Medical Device Maker Deal Valued at More Than $4 Billion

  • Carlyle in exclusive talks to acquire Baxter’s Vantive for over $4 billion
  • Vantive had about $4.5 billion in revenue last year and more than 22,000 employees
  • Dealmaking is slowly coming back to life
  • Private equity leveraged buyouts up 45% from last year

Private-equity firm Carlyle Group is in advanced talks to acquire Baxter’s kidney care spinoff Vantive for more than $4 billion, including debt. The deal would be Carlyle’s latest at a time when private-equity dealmaking is slowly coming back to life. Private equity leveraged buyouts are up 45% from last year according to data provider Dealogic, with $109.2 billion struck through early July.

Factuality Level: 8
Factuality Justification: The article provides relevant and accurate information about Carlyle’s potential acquisition of Vantive, the current state of private-equity dealmaking, and Baxter’s previous plans for its kidney care company. It also includes details on the revenue and employee count of the business. The article is mostly factual with a brief mention of Carlyle’s internal changes.
Noise Level: 3
Noise Justification: The article provides relevant information about a specific deal between Carlyle and Baxter’s kidney care spinoff Vantive, but it lacks in-depth analysis or exploration of the broader implications of this deal. It also does not offer much insight into the state of private equity dealmaking beyond mentioning that it is ‘slowly coming back to life.’ The article could benefit from more context and evidence to support its claims.
Public Companies: Baxter (BAX)
Private Companies: Carlyle Group
Key People: Steve Wise (former head of healthcare, now co-head of Americas Corporate Private Equity at Carlyle), Laura Cooper (author)

Track all markets on TradingView

Financial Relevance: Yes
Financial Markets Impacted: Private equity and medical device sectors
Financial Rating Justification: The article discusses a potential acquisition of a medical device maker by private-equity firm Carlyle, which impacts the private equity dealmaking market and the medical device sector. It also mentions the financial details of the acquisition and the current state of private equity dealmaking.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no extreme event mentioned in the text.

Reported publicly: www.wsj.com